Protein Assassins: Screening for Improved Degraders to Reverse Tumor Immortality
ISEF · 2026 Biomedical and Health Sciences Third Award
Overview
Glioblastoma (GBM) is the most common malignant brain cancer in adults, and patient survival still remains low. However, 83% of GBM cases have Telomerase Reverse Transcriptase promoter (TERTp) mutations, enabling the GA-binding protein (GABP) transcription factor complex to bind and reactivate TERT expression. While directly targeting telomerase has systemic toxicity, targeting GABP may allow tumor-specific TERT silencing. Last year, I designed a GABPA dominant negative fused to an E3 ubiquitin ligase to create a biological Proteolysis-Targeting Chimera (bioPROTAC) targeting GABP, reducing TERT expression in glioma cells. To improve the degrader’s potency, I took a two-pronged approach: 1) degrader stability could be improved by removing external lysines that may serve as ubiquitination sites, and 2) degrader efficiency could be improved by enhancing the binding affinity to GABPA. First, candidate lysine residues were identified and substituted to prevent potential self-ubiquitination and auto-degradation of the bioPROTAC. Second, protein structure modeling algorithms, like AlphaFold2 and Structural-Evolution, were used to assess the in silico affinity maturation of the GABPA binding domain, narrowing thousands of candidates to 116. Following in vitro experimental validation, the best-performing variant was identified, showing a 73-95% decrease in TERT expression across different cancer cell lines. This study demonstrates that integrating machine learning models into therapeutic design dramatically accelerates screening, not only for brain tumors but also for other tumor types. Validation of these results serves as a proof-of-concept, providing a powerful example for the potential applications in other transcription factor-regulated diseases.
Awards (1)
- Third Award of $1,200 $1,200
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2025
Molecular Arsonists: Degrading Oncogenic Transcription Factors to Reverse Tumor Cell Immortality
ISEF · 2024
Grand Theft Transcription Factor: Reversing Tumor Cell Immortality by Transcription Factor Relocalization
AJAS · 2026
Grand Theft Transcription Factor: Reversing Tumor Cell Immortality by Relocalization
CSEF · 2023
Novel Strategies for the Reversal of Cancer Cell Immortality
ISEF · 2023
Novel Strategies for the Reversal of Cancer Cell Immortality
CSEF · 2026
Structure-Guided In Silico Engineering of PROTACs for Targeted S100A16 Proteasomal Degradation via E3 Ligase Recruitment
JSHS · 2025
Molecular Arsonists: Degrading Oncogenic Transcription Factors to Reverse Tumor Immortality
AJAS · 2024
A Novel Strategy for the Reversal of Tumor Cell Immortality
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair